HIGH-DOSE ETOPOSIDE FOR REFRACTORY MALIGNANCIES - A PHASE-I STUDY

Google Scholar
  • 1 January 1984
    • journal article
    • research article
    • Vol. 68  (12) , 1471-1474
Abstract
In a group of 22 patients with progressive disseminated malignancies, the dose of etoposide was escalated to define dose-limiting extramedullary toxicity, which was oropharyngeal mucositis at a dose level of 3.5 g/m2. Bone marrow toxicity was completely reversible. No cumulative toxicity was seen. Partial responses were seen in 9 patients. In 2 of 3 patients with CNS metastases, improvement was seen. Etoposide is a suitable drug for high-dose chemotherapy.